India, Sept. 22 -- TriSalus Life Sciences, Inc. (TLSI), an oncology-focused medical technology company, said the U.S. Food and Drug Administration has granted 510(k) clearance to TriNav Advance, expanding its Pressure-Enabled Drug Delivery, or PEDD portfolio for liver embolization procedures.
Liver embolization is an international procedure used to deliver therapy to tumors by targeting their blood supply. TriNav Advance is designed to support drug delivery to small, distal vessels while maintaining the delivery and off-target protection associated with the company's PEDD technology.
The device can be used with a compatible delivery microcatheter, allowing interventional radiologists to select the microcatheter based on the procedure and ...